Westbourne Investment Advisors Inc. Boosts Stake in Pfizer Inc. (NYSE:PFE)

Westbourne Investment Advisors Inc. lifted its holdings in Pfizer Inc. (NYSE:PFE) by 2.8% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 20,404 shares of the biopharmaceutical company’s stock after purchasing an additional 560 shares during the quarter. Westbourne Investment Advisors Inc.’s holdings in Pfizer were worth $733,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also bought and sold shares of the company. Heritage Way Advisors LLC increased its position in shares of Pfizer by 0.6% during the 2nd quarter. Heritage Way Advisors LLC now owns 57,524 shares of the biopharmaceutical company’s stock valued at $2,492,000 after purchasing an additional 354 shares during the last quarter. Natixis purchased a new stake in shares of Pfizer in the second quarter worth approximately $258,466,000. Machina Capital S.A.S. raised its holdings in shares of Pfizer by 14.4% in the second quarter. Machina Capital S.A.S. now owns 43,837 shares of the biopharmaceutical company’s stock worth $1,899,000 after buying an additional 5,522 shares during the period. Integrated Wealth Concepts LLC raised its holdings in shares of Pfizer by 14.2% in the second quarter. Integrated Wealth Concepts LLC now owns 68,060 shares of the biopharmaceutical company’s stock worth $2,840,000 after buying an additional 8,445 shares during the period. Finally, Annex Advisory Services LLC raised its holdings in shares of Pfizer by 0.7% in the second quarter. Annex Advisory Services LLC now owns 51,785 shares of the biopharmaceutical company’s stock worth $2,243,000 after buying an additional 382 shares during the period. Hedge funds and other institutional investors own 71.66% of the company’s stock.

A number of equities analysts have weighed in on the company. Zacks Investment Research upgraded Pfizer from a “sell” rating to a “strong-buy” rating and set a $38.00 price objective for the company in a research note on Tuesday, October 1st. Bank of America initiated coverage on Pfizer in a report on Wednesday, October 16th. They issued a “neutral” rating and a $37.00 price objective on the stock. UBS Group reiterated a “neutral” rating and issued a $43.00 price objective on shares of Pfizer in a report on Monday, August 5th. Morgan Stanley decreased their price objective on Pfizer from $40.00 to $38.00 and set an “equal weight” rating on the stock in a report on Tuesday, August 27th. Finally, DZ Bank upgraded Pfizer from a “sell” rating to a “hold” rating and set a $36.00 price objective on the stock in a report on Wednesday, August 28th. Twelve research analysts have rated the stock with a hold rating, four have given a buy rating and one has assigned a strong buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus price target of $44.47.

In other Pfizer news, Director Scott Gottlieb bought 3,000 shares of Pfizer stock in a transaction dated Friday, August 23rd. The stock was bought at an average price of $34.72 per share, with a total value of $104,160.00. Following the completion of the transaction, the director now owns 3,000 shares in the company, valued at approximately $104,160. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, major shareholder Pfizer Inc bought 50,000 shares of Pfizer stock in a transaction dated Tuesday, September 17th. The stock was acquired at an average cost of $18.00 per share, with a total value of $900,000.00. The disclosure for this purchase can be found here. Company insiders own 0.09% of the company’s stock.

NYSE PFE traded up $0.10 on Tuesday, reaching $36.56. The stock had a trading volume of 427,405 shares, compared to its average volume of 16,028,038. The firm has a market capitalization of $202.08 billion, a price-to-earnings ratio of 12.19, a P/E/G ratio of 2.16 and a beta of 0.66. The company has a quick ratio of 1.21, a current ratio of 1.47 and a debt-to-equity ratio of 0.60. Pfizer Inc. has a 12-month low of $33.97 and a 12-month high of $46.47. The stock has a fifty day moving average price of $36.25 and a two-hundred day moving average price of $39.64.

Pfizer (NYSE:PFE) last issued its earnings results on Monday, July 29th. The biopharmaceutical company reported $0.80 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.75 by $0.05. The company had revenue of $13.26 billion during the quarter, compared to analysts’ expectations of $13.43 billion. Pfizer had a net margin of 23.58% and a return on equity of 28.10%. The firm’s quarterly revenue was down 1.5% compared to the same quarter last year. During the same period last year, the company posted $0.77 earnings per share. Sell-side analysts forecast that Pfizer Inc. will post 2.82 earnings per share for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Monday, December 2nd. Shareholders of record on Friday, November 8th will be issued a dividend of $0.36 per share. The ex-dividend date is Thursday, November 7th. This represents a $1.44 annualized dividend and a yield of 3.94%. Pfizer’s dividend payout ratio (DPR) is currently 48.00%.

About Pfizer

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It offers medicines and vaccines in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases under the Lyrica, Chantix/Champix, Eliquis, Ibrance, Sutent, Xalkori, Inlyta, Xtandi, Enbrel, Xeljanz, Eucrisa, BeneFix, Genotropin, and Refacto AF/Xyntha brands.

Further Reading: Quantitative Easing

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit